UEYAMA SEIICHI | Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd.

スポンサーリンク

概要

• UEYAMA SEIICHIの詳細を見る
• 同名の論文著者
• Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd.の論文著者

Pharmacology, Lead Optimization, Drug Innovation and Approval Division, Aventis Pharma Ltd. | 論文

• The active metabolite of leflunomide, A771726, inhibits both the generation of and the bone-resorbing activity of osteoclasts by acting directly on cells of the osteoclast lineage

もっと見る

スポンサーリンク